Kalbitor News
Most Popular Kalbitor Story
Dyax investors bid up shares on FDA's Kalbitor approval
Dyax shares rocketed up 38 percent yesterday evening after the developer announced that the FDA had approved its lead drug Kalbitor (also known as ecallantide or DX-88) for patients with hereditary Read more...
Latest Headlines
- December 2, 2009
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
